

097926323

WO 00/62071

PCT/EP00/03347

1

SEQUENCE PROTOCOL

<110> Wilex Biotechnology GmbH

<120> Diagnostic and therapeutic use of antibodies
against the urokinase receptor

<130> 19116PEP

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 354

<212> DNA

<213> artificial sequence

<220>

<223> description of artificial sequence:
phage sequence

<220>

<221> CDS

<222> (1)..(354)

<400> 1

cag gtg caa ctg cag cag tca gga cct gag ttg gtg aag cct ggg gct 48
Gln Val Gln Leu Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15

tta gtg aag ata tcc tgc aag gct tct ggt tac agt ttc aca agc tac 96
Leu Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30

gat ata aat tgg gtg aag cgg agg cct gga cag gga ctt gag tgg att 144
Asp Ile Asn Trp Val Lys Arg Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

gga tgg att ttt cct gga gat ggt agt acc aat tac aat gag aaa ttc 192
Gly Trp Ile Phe Pro Gly Asp Gly Ser Thr Asn Tyr Asn Glu Lys Phe
50 55 60

aag gac aag gcc aca ctg act gct gac aaa tcc tcc agc aca gcc tac 240
Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr

2

65

70

75

80

atg cag ctc aac agc ctg act tct gag aac tct gca gtc tat ttc tgt 288
Met Gln Leu Asn Ser Leu Thr Ser Glu Asn Ser Ala Val Tyr Phe Cys
85 90 95

gca aga gat gga agt atg ggg ggg ttt gac tac tgg ggc caa ggg acc 336
Ala Arg Asp Gly Ser Met Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

acg gtc acc gtc tcc tca 354
Thr Val Thr Val Ser Ser
115

<210> 2
<211> 118
<212> PRT
<213> artificial sequence
<223> description of artificial sequence:
phage sequence

<400> 2
Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15

Leu Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30

Asp Ile Asn Trp Val Lys Arg Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Trp Ile Phe Pro Gly Asp Gly Ser Thr Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Asn Ser Leu Thr Ser Glu Asn Ser Ala Val Tyr Phe Cys
85 90 95

Ala Arg Asp Gly Ser Met Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

Thr Val Thr Val Ser Ser
115

WO 00/62071

PCT/EP00/03347

3

<210> 3
<211> 324
<212> DNA
<213> artificial sequence

<220>
<221> CDS
<222> (1)..(324)

<220>
<223> description of artificial sequence:
phage sequence

<400> 3
gat gtt ttg atg acc caa act cca aaa ttc atg tcc aca tca gta gga 48

Asp Val Leu Met Thr Gln Thr Pro Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15

gac agg gtc agc atc acc tgc aag gcc agt cag aat gtt cgt act act 96
Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Thr
20 25 30

gta gcc tgg tat caa gag aaa cca ggg cag tct cct aaa gca ctg att 144
Val Ala Trp Tyr Gln Glu Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
35 40 45

tac ttg gca tcc aac cgg cac act gga gtc cct gat cgc ttc aca ggc 192
Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

agt gga tct gga aca gat ttc act ctc acc att agc aat gtg caa tct 240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
65 70 75 80

gaa gac ctg gca gat tat ttc tgt ctg caa cat tgg aat tat ccg tac 288
Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Tyr
85 90 95

acg ttc gga ggg ggc acc aag ctg gaa atc aaa cgg 324
Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105

<210> 4
<211> 108
<212> PRT
<213> artificial sequence
<223> description of artificial sequence:

WO 00/62071

PCT/EP00/03347

4

phage sequence

<400> 4

Asp Val Leu Met Thr Gln Thr Pro Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15

Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Thr
20 25 30

Val Ala Trp Tyr Gln Glu Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
35 40 45

Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
65 70 75 80

Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Tyr
85 90 95

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105

WO 00/62071

PCT/EP00/03347

1

SEQUENZPROTOKOLL

<110> Wilex Biotechnology GmbH

<120> Diagnostischer und therapeutischer Einsatz von
Antikörpern gegen den Urokinase-Rezeptor

<130> 19116PEP

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 354

<212> DNA

<213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz:
Phagensequenz

<220>

<221> CDS

<222> (1)..(354)

<400> 1

cag gtg caa ctg cag cag tca gga cct gag ttg gtg aag cct ggg gct 48
Gln Val Gln Leu Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15

tta gtg aag ata tcc tgc aag gct tct ggt tac agt ttc aca agc tac 96
Leu Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30

gat ata aat tgg gtg aag cgg agg cct gga cag gga ctt gag tgg att 144
Asp Ile Asn Trp Val Lys Arg Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

gga tgg att ttt cct gga gat ggt agt acc aat tac aat gag aaa ttc 192
Gly Trp Ile Phe Pro Gly Asp Gly Ser Thr Asn Tyr Asn Glu Lys Phe
50 55 60

aag gac aag gcc aca ctg act gct gac aaa tcc tcc agc aca gcc tac 240
Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr

WO 00/62071

PCT/EP00/03347

2

65

70

75

80

atg cag ctc aac agc ctg act tct gag aac tct gca gtc tat ttc tgt 288
 Met Gln Leu Asn Ser Leu Thr Ser Glu Asn Ser Ala Val Tyr Phe Cys
 85 90 95

gca aga gat gga agt atg ggg ggg ttt gac tac tgg ggc caa ggg acc 336
 Ala Arg Asp Gly Ser Met Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

acg gtc acc gtc tcc tca 354
 Thr Val Thr Val Ser Ser
 115

<210> 2

<211> 118

<212> PRT

<213> Künstliche Sequenz

<223> Beschreibung der künstlichen Sequenz:
 Phagensequenz

<400> 2

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Leu Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30

Asp Ile Asn Trp Val Lys Arg Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Trp Ile Phe Pro Gly Asp Gly Ser Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Met Gln Leu Asn Ser Leu Thr Ser Glu Asn Ser Ala Val Tyr Phe Cys
 85 90 95

Ala Arg Asp Gly Ser Met Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Thr Val Thr Val Ser Ser
 115

WO 00/62071

PCT/EP00/03347

3

<210> 3
<211> 324
<212> DNA
<213> Künstliche Sequenz

<220>
<221> CDS
<222> (1)...(324)

<220>
<223> Beschreibung der künstlichen Sequenz:
Phagensequenz

<400> 3

gat	gtt	ttg	atg	acc	caa	act	cca	aaa	ttc	atg	tcc	aca	tca	gta	gga	48
Asp	Val	Leu	Met	Thr	Gln	Thr	Pro	Lys	Phe	Met	Ser	Thr	Ser	Val	Gly	
1		5					10							15		

gac	agg	gtc	agc	atc	acc	tgc	aag	gcc	agt	cag	aat	gtt	cgt	act	act	96
Asp	Arg	Val	Ser	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asn	Val	Arg	Thr	Thr	
20							25							30		

gta	gcc	tgg	tat	caa	gag	aaa	cca	ggg	cag	tct	cct	aaa	gca	ctg	att	144
Val	Ala	Trp	Tyr	Gln	Glu	Lys	Pro	Gly	Gln	Ser	Pro	Lys	Ala	Leu	Ile	
35							40							45		

tac	ttg	gca	tcc	aac	cgg	cac	act	gga	gtc	cct	gat	cgc	ttc	aca	ggc	192
Tyr	Leu	Ala	Ser	Asn	Arg	His	Thr	Gly	Val	Pro	Asp	Arg	Phe	Thr	Gly	
50							55							60		

agt	gga	tct	gga	aca	gat	ttc	act	ctc	acc	att	agc	aat	gtg	caa	tct	240
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Asn	Val	Gln	Ser	
65							70			75				80		

gaa	gac	ctg	gca	gat	tat	ttc	tgt	ctg	caa	cat	tgg	aat	tat	ccg	tac	288
Glu	Asp	Leu	Ala	Asp	Tyr	Phe	Cys	Leu	Gln	His	Trp	Asn	Tyr	Pro	Tyr	
85							90							95		

acg	ttc	gga	ggg	ggc	acc	aag	ctg	gaa	atc	aaa	cgg					324
Thr	Phe	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg						
100							105									

<210> 4
<211> 108
<212> PRT
<213> Künstliche Sequenz
<223> Beschreibung der künstlichen Sequenz:

WO 00/62071

PCT/EP00/03347

4

Phagensequenz

<400> 4

Asp Val Leu Met Thr Gln Thr Pro Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15

Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Thr
20 25 30

Val Ala Trp Tyr Gln Glu Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
35 40 45

Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
65 70 75 80

Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Tyr
85 90 95

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105